PATHFAST®
Analyzer

The PATH to better cardiac care starts here

The wait is over

The only point-of-care high-sensitivity cardiac troponin (hs-cTn) is now available

Learn more

Laboratory excellence, propelling ED performance

The PATHFAST Analyzer accelerates urgent cardiac care decisions in the Emergency Department (ED) with reliable, lab-quality testing at the point of care.

PATHFAST meets ED goals of accuracy, efficiency & flexibility

Results available in under 17 minutes

Flexibility to run up to 6 tests at once

Space-saving benchtop design for the ED or STAT lab

User-friendly operation

Eliminating preanalytical delays associated with core-laboratory testing has been shown to:

Accelerate care decisions by
40 minutes1
Reduce length of stay by
34 minutes1

The wait is over: The only hs-cTn at the point of care now available

PATHFAST hs-cTnI-II

Finally, EDs can access an optimal solution to accelerate the assessment and disposition of patients with suspected acute coronary syndrome (ACS).

High-sensitivity cardiac troponin is the preferred assay to be used as an aid in the diagnosis of acute myocardial infarction (AMI)

Lab-quality results

  • 6% CV at the 99th percentile cutoff of 29 ng/L2
  • 4.1 ng/L limit of quantitation (LoQ, I.e. functional sensitivity)2

When and where you need them

  • Results in 17 minutes within care pathway
  • Run up to 6 tests at once

Optimizing ED performance

  • Proven performance in 0/1, 0/2, and 0/3 h accelerated diagnostic protocols3–5

Access to quicker test results can help clinicians identify urgent cardiac concerns sooner, reduce length of stay, and improve patient satisfaction.

Discover more resources

Visit the online resource center for additional education and support materials.

Visit resource center

NT-proBNP is used to aid in the diagnosis of patients with suspected congestive acute heart failure (CHF). Rapid results at the point of care inform rapid risk stratification and admission decisions.

  • More accurate diagnosis and improved risk stratification for patients with acute dyspnea6
  • Strongest independent predictor of a final diagnosis of acute CHF7
  • NT-proBNP plus clinical judgment is superior to either alone7

Discover the best of both worlds

hs-cTn-II + NT-proBNP

PATHFAST is the only point-of-care system to offer both hs-cTnI-II and NT-proBNP, two gold-standard cardiac biomarker tests, on a single platform.

A complete menu of urgent STAT tests

PATHFAST facilitates decisions for a range of assays including:

  • hs-cTnI-II
  • cTnI-II
  • D-Dimer
  • CK-MB
  • NT-proBNP
  • hs-CRP
  • Myoglobin

Proactive support every step of the way

Polymedco is committed to being one of the easiest companies to do business within healthcare. We work closely with laboratorians, clinicians, and administrators to maximize the value of our tests in every ED.

Learn more about the dedicated support you can expect from a PATHFAST partnership

Learn more

Technical specifications

Instrument type Benchtop Analyzer
Throughput Up to 6 samples or assays per run
Measuring time <17 minutes for to up to 6 simultaneous samples
Sampling material Whole blood, plasma
Measuring principle Chemiluminescence enzyme immunoassay technology (CLEIA) combined with proprietary Magtration® technology
Reaction temperature 37.5° C
Sample volume 100 µL
Wavelength 300 – 650 nm
Data storage Patient data: 1000
QC data 1800
CAL data 300
Data transfer ASTM standard
Dimensions 13.5 in. W x 22.4 in. D x 18.7 in. H
Weight 62 lbs
Electrical requirements 100 – 240 Vac
Monitor/keyboard LCD Touchscreen
Printer/PC Integrated
Interface RS-232C
Calibration Factory calibration, 2-point calibration every 4 weeks
24-h operation (standby)

Ordering information

Contact us

Learn more about the dedicated support you can expect from a PATHFAST partnership

Learn more

Connect with us

Fill out the form to submit your information.

References:

  1. Goyder C, Tan PS, Verbakel J, et al. Impact of point-of-care panel tests in ambulatory care: a systematic review and meta-analysis. BMJ Open. 2020;10(2):e032132. doi:10.1136/bmjopen-2019-032132
  2. Point of care cardiac troponin I and T assay analytical characteristics. IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Accessed March 13, 2024. https://ifcc.org/ifcc-education-division/emd-committees/committee-on-clinical-applications-of-cardiac-bio-markers-c-cb/biomarkers-reference-tables/
  3. Sörensen NA, Neumann JT, Ojeda F, et al. Diagnostic evaluation of a high-sensitivity troponin I point-of-care assay. Clin Chem. 2019;65(12):1592-1601. doi:10.1373/clinchem.2019.307405
  4. Koechlin L, Boeddinghaus J, Lopez-Ayala P, et al. External validation of the 0/1h-algorithm and derivation of a 0/2h-algorithm using a new point-of-care Hs-cTnI assay. Am Heart J. 2024;268:104-113. doi:10.1016/j.ahj.2023.11.014
  5. Lehmacher J, Sörensen NA, Twerenbold R, et al. Diagnostic and prognostic value of the sex-specific 99th percentile of four high-sensitivity cardiac troponin assays in patients with suspected myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2024;13(1):3-12.doi:10.1093/ehjacc/zuad131
  6. Bingisser R, Cairns CB, Christ M, et al. Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: Current status and future perspectives. Am Heart J. 2013;166(4). doi:10.1016/j.ahj.2013.06.012
  7. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the Emergency Department (Pride) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.033